The net worth of the market share of the anti-biofilm wound dressing is predicted to reach from USD 782.60 million in 2023 to over USD 1939.45 million by 2033, recording a CAGR of 9.5% between 2023 and 2033. Incidence rates for chronic and acute wounds are expected to increase, driving demand for anti-biofilm wound dressings.
As chronic diseases such as diabetes, cancer, and other autoimmune diseases become prevalent. Antimicrobial resistance and unhealthy sedentary lifestyles, tobacco, and alcohol consumption are also contributing to the rising non-communicable disease prevalence.
A study published by the Centres for Disease Control and Prevention in 2020. The report estimates that there are 34.2 million diabetics in the United States which is 10.5% of the population. An estimated 26.8 million people in the United States have been diagnosed with diabetes. However, 7.3 million people have not yet been diagnosed with diabetes, according to a similar report.
Exclusive Offer: 30% Off on Regional Reports
Get a free sample report and customize your regions for a 30% discount on your regional report!
For instance, according to ASEP Medical Holdings Inc., the Antibiofilm/Anti-inflammatory Peptide Technology that was developed with help from the United States Army Medical Research and Materiel Command was successful in February 2022.
| Attributes | Details |
|---|---|
| Anti-biofilm Wound Dressing Market Value (2023) | USD 782.60 million |
| Anti-biofilm Wound Dressing Market Expected Value (2033) | USD 1939.45 million |
| Anti-biofilm Wound Dressing Market Projected CAGR (2023 to 2033) | 9.5% |
According to the World Health Organization, cancer is the leading cause of death worldwide, killing one in six people every year. More than 70 percent of cancer-related deaths occur in countries with low or middle-income groups. Increased incidences of chronic diseases result in prolonged hospitalizations and surgeries, which would increase the demand for anti-biofilm wound dressings.
Due to the increasing participation in sports, injuries are becoming more common. For example, Stanford Children's Health estimates that about 3.5 million injuries occur among children in the United States every year and 21 percent of these injuries are traumatic in nature.
The Canadian Institute for Health Information (CIHI) reports that more than 17,655 individuals have been hospitalized for sports-related injuries in 2017. Therefore, more injuries are occurring to fuel the demand for the global market.
| Historical CAGR | 8.2% |
|---|---|
| Historical Market Value (2022) | USD 652.96 million |
| Forecast CAGR | 9.5% |
The incidence of diabetic foot ulcers in diabetics ranges from 2% to 10%, according to studies conducted by B Braun Melsungen AG in 2018. The American College of Physicians reports that the number of newly diagnosed cases of diabetic foot ulcers was about 6.3% in 2017. The incidence of diabetic foot ulcers in a lifetime varies from 19% to 34%. Since anti-biofilm dressings are highly recommended for treating chronic wounds, market growth is expected to grow at a high rate.
Most surgical wounds following cancer surgery are deep and large, resulting in exudates that need to be managed daily. As a result, the growing prevalence of chronic illnesses is expected to boost product demand, thus pushing the global anti-biofilm wound dressing market upward. Anti-biofilm wound dressings, such as iodine and silver-based wound dressings, help manage wounds and prevent infection.
according to the World Health Organization (WHO)., about 1,000,000 Indians are affected by serious or moderate burns in India each year, The market may grow due to the rise in injuries caused by road accidents, trauma events, and burns around the globe.
With the rise of chronic diseases like cancer, diabetes, and Deep Vein Thrombosis (DVT), the likelihood of acquiring chronic wounds rises, which is expected to drive market growth. Diabetic foot ulcers are wounds that typically occur in 15% of diabetic patients.
About 6% of these people are hospitalized due to infection, thus wound treatment is necessary. According to the National Cancer Institute, in 2018, there were 1,735,350 diagnosed cancer cases in the United States. Due to the rise in cancer cases, the demand for anti-biofilm wound dressings may increase.
In the United States, approximately 900,000 people are affected by DVT each year. With the rising prevalence of DVT, patients are more likely to develop venous ulcers. Approximately 20 to 50 percent of them may experience Post-thrombotic Syndrome (PTS), and 5% to 10% may suffer from venous ulcers.
The market is expected to expand further due to the increasing prevalence of pressure ulcers, commonly referred to as bed sores or pressure sores. According to the European Pressure Ulcer Advisory Panel, 5% of community nursing patients and 10% of hospital patients may develop pressure ulcers at some point in their lives. Therefore, the growing prevalence of chronic ulcers is expected to propel the demand for the anti-biofilm wound dressing market.
Through the provision of low-risk procedures in a convenient setting, Ambulatory Surgical Centers (ASCs) are revolutionizing healthcare delivery. Thus offering lower costs than other medical settings, such as hospitals, ASCs are anticipated to grow in popularity as Medicare spends more on improving ASCs.
Over 3.4 million Medicare Fee-For-Service (FFS) beneficiaries were treated in 5,603 hospitals certified by Medicare in 2017. Medicare beneficiaries spent USD 4.6 billion on ASC services in 2017. A growing number of ASCs is expected to drive the overall market. Previously, ASCs offered a single specialty.
There has been an increase in multispecialty ASCs in the United States from 1,802 in 2015 to 1,878 in 2017, as these settings are increasingly used for different applications. Market growth is expected to be driven by the fact that they can perform special treatments, including pain management, orthopedics, and ophthalmology.
The number of wound patients occupying hospital beds is approximately 25% to 40%. A wound takes a long time to heal and requires many resources. The human cost associated with wounds is prolonged hospital stays, chronic pain, and distress.
For example, a stage IV pressure ulcer causes considerable pain, adding around three months or longer to hospital stays, thereby increasing the patient burden. Similarly, wound infections can lead to inflammation and pain, which will require surgical intervention or anti-biofilm dressings to prevent wound infections from developing.
The cost of wound care in acute settings can reach 15% to 20% of materials, 30% to 35% of nurse time, and more than 50% of hospitalization. The wound dressings must be changed frequently, which adds to the cost of treatment.
It is estimated that chronic wounds cost between USD 3.48 million and USD 4.32 million per year, accounting for about 2% to 3% of the healthcare budget. As a result, high treatment costs may result in a decrease in the adoption of anti-biofilm wound dressings, which, in turn, may hinder the market growth during the forecast period.
Check Free Sample Report & Save 40%!
Select your niche segments and personalize your insights for smart savings. Cut costs now!
Approximately 50 million people are affected annually by vehicle accidents, including slips, trips, burns, and road accidents. Wound dressings that promote wound healing and are anti-biofilm, the market is driven by the increase in accidents, slips, trips, burns, and other ailments.
Health and Safety Middle East (HSME) indicates that hundreds of workers suffer injuries in the workplace each year as a result of trips, slips, and falls. An increase in burn injuries is also expected to drive the market's growth. It is estimated that 1.1 million burn injuries occur in the United States every year. Approximately 50,000 of these patients require hospitalization, which increases the need for wound dressings with anti-biofilms.
Expanding the Penetration of Chemical Segment:
Based on the Mode of Mechanism: The global anti-biofilm wound dressing devices market has been segmented into physical, chemical, and biological. The chemical segment is expected to dominate the overall market and record a significant CAGR of 9.9% during the forecast period.
The chemical mode of mechanism is expected to expand substantially over the forecast period. There is a growing prevalence of chronic wounds and a growing number of surgeries worldwide, so this is inevitable.
A chemical-based anti-biofilm wound dressing improves wound healing efficiency and recovery efficiency by targeting biofilms on multiple levels. They can reduce the accumulation of biofilm on wounds and reduce the risk of recontamination with microorganisms.
A significant increase in Research and Development activities and innovation is taking place in the anti-biofilm wound dressing industry, which is fuelled by the physical mode of mechanism. It was announced in June 2020 that the United Kingdom National Biofilms Innovation Centre would be providing a grant of USD 28,949.03 million for research and the introduction of enhanced product lines related to managing, engineering, and detecting biofilms.
There are three types of physical modes of debridement: manual debridement, pulse electrical field debridement, and ultrasound debridement.
Based on wound type, the anti-biofilm wound dressing market is segmented into acute and chronic wounds. In 2023, surgical & traumatic wounds held a significant share, due to the increasing number of trauma cases worldwide. The acute wound segment dominated the market. This segment is expected to grow by 9.3%.
Traumatic wounds are sudden injuries that can range from minor ones to severe ones, like gunshot wounds. Such wounds include abrasions, lacerations, skin tears, bites, and penetrating trauma wounds. Anti-biofilm wound dressings are ideal for treating these types of wounds.
When treating traumatic wounds with these dressings, the body's underlying tissues are repaired, foreign particles are removed, and wounds are allowed to drain. Preventing infections and promoting healing, these steps can promote segment growth and help prevent infections.
| Region | North America |
|---|---|
| Country | The United States |
| CAGR | 9.5% |
| Region | Europe |
|---|---|
| Country | Germany |
| CAGR | 8.6% |
| Region | Europe |
|---|---|
| Country | The United Kingdom |
| CAGR | 9.1% |
The United States accounts for a significant market share in North America r and is estimated to record a CAGR of 9.5%. An increase in chronic wounds, a rise in road accidents, and the presence of large ambulatory surgical centers are a few factors that drive market growth in this region. Well-developed infrastructure, skilled staff, and increased healthcare expenditures contribute to this region's market growth.
Europe's significant region, the United Kingdom, is expected to record a CAGR of 9.1%. Wounds are a growing concern in Europe, and their treatment involves a variety of resources. Various surveys were conducted in the United Kingdom.
According to statistics, three to four wounds per 1,000 people are reported. Diabetic foot ulcers are estimated to be diagnosed between 400,000 and 600,000 each year, along with venous leg ulcers that number about one million.
The United Kingdom's anti-biofilm wound dressing market is expected to grow due to the aging population and the increased prevalence of long-term chronic conditions.
Various studies conducted in China estimate that around 100 million patients require wound care every year, and about 30 million of these are skin wounds. These factors are expected to drive the market in China. An increase in healthcare expenditure, an increase in road accidents, and a significant amount of patient population are expected to drive the market.
The number of wound care centers in China has increased from 16 in 2010 to 357 in 2019. In December 2019, the National Health Commission of China released a notice for promoting the management of diagnosis and treatment of chronic skin wounds. This system includes setting up wound treatment departments and training specialized doctors & nurses.
The population of China is covered by social health insurance for more than 95%, which includes all primary healthcare institutions, public hospitals, as well as some private hospitals. As a result, chronic wounds are on the rise in China, government initiatives are being implemented, and healthcare facilities are being improved, which is expected to drive the market.
It seems that several new industry players are concentrating their efforts on consolidating their distribution channels. They are also focusing on direct marketing as a way of getting a foothold in the anti-biofilm wound dressing market.
To gain an advantage over their competitors, numerous key players are still focusing on partnerships and innovation in product development as their primary strategies to gain an advantage over their competitors.
For instance, a telehealth platform developed by Wound Pros Inc. in January 2021 enables patients and professionals to communicate. Their app, RITA, facilitates new wound measurements and diagnostics.
Inflows of Funds are Expected as Market Players Expand their Footprints
Leading companies are leaving no stone unturned to gain a competitive edge and boost the anti-biofilm wound dressing market outlook.
For Instance:
| Attribute | Details |
|---|---|
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | USD million for Value and MT for Volume |
| Key Regions Covered | North America; Latin America; Europe; The Middle East and Africa (MEA); East Asia |
| Key Countries Covered | The United States, Canada, Brazil, Mexico, Chile, Peru, Germany, The United Kingdom., Spain, Italy, France, Russia, Poland, China, India, Japan, Australia, New Zealand, GCC Countries, North Africa, and South Africa |
| Key Segments Covered | Mode of Mechanism, Wound Type, End User, Region |
| Key Companies Profiled | ConvaTec; Smith & Nephew PLC; Urgo Medical; Coloplast; 3M |
| Report Coverage | Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives |
| Customization & Pricing | Available upon Request |
The market is valued at USD 782.6 million in 2023.
The market is anticipated to secure a valuation of USD 1,939.45 million by 2033.
The chemical segment is expected to lead the market with a CAGR of 9.9% during the forecast period.
India, Japan, and China dominate the Asian market.
| Market CAGR (2023 to 2033) | 5.2% |
|---|---|
| Market Size (2023) | USD 4.54 billion |
| Market Size (2033) | USD 7.52 billion |
Explore Therapeutic Device Insights
View Reports
Anti-biofilm Wound Dressing Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
